Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13819771 | 0.90 | TAAR1 (0.40) | APPCYP1A2CYP2D6MMETAAR1 | |
| SCHEMBL13819785 | 0.86 | TAAR1 (0.40) | APPCYP1A2CYP2D6MMETAAR1 | |
| SCHEMBL26565775 | 0.78 | KMT2A (0.42) | CYP1A2CYP2D6MMETAAR1SIGMAR1 | |
| SCHEMBL11570604 | 0.78 | CYP1A2 (0.44) | CYP1A2CYP2D6APEX1PMP22SIGMAR1 | |
| SCHEMBL1498212 | 0.76 | CYP1A2 (0.42) | CYP1A2CYP2D6SIGMAR1 | |
| SCHEMBL8142452 | 0.72 | APP (0.57) | APPTAAR1HTR2A | |
| SCHEMBL13721762 | 0.72 | EPHX2 (0.44) | APPMME | |
| SCHEMBL13918175 | 0.72 | APP (0.67) | APP | |
| SCHEMBL13430004 | 0.72 | MME (0.36) | APPMMETAAR1SIGMAR1 | |
| SCHEMBL24568712 | 0.71 | CYP1A2 (0.53) | APPCYP1A2CYP2D6APEX1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051246-B2 | Compound having trimethylene structure, polymer compound containing unit that has trimethylene structure, and reactive compound having trimethylene structure | HITACHI CHEMICAL COMPANY, LTD. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120289674-A1 | COMPOUND HAVING TRIMETHYLENE STRUCTURE, POLYMER COMPOUND CONTAINING UNIT THAT HAS TRIMETHYLENE STRUCTURE, AND REACTIVE COMPOUND HAVING TRIMETHYLENE STRUCTURE | KANAGAWA UNIVERSITY (JP) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289674-A1 | COMPOUND HAVING TRIMETHYLENE STRUCTURE, POLYMER COMPOUND CONTAINING UNIT THAT HAS TRIMETHYLENE STRUCTURE, AND REACTIVE COMPOUND HAVING TRIMETHYLENE STRUCTURE | SUV39H2, SUV39H1, EZH1 | APP 2060/4885CYP1A2 423/4885CYP2D6 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.